The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImmupharma Regulatory News (IMM)

Share Price Information for Immupharma (IMM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.19
Bid: 2.10
Ask: 2.18
Change: 0.03 (1.39%)
Spread: 0.08 (3.81%)
Open: 2.11
High: 2.19
Low: 2.11
Prev. Close: 2.16
IMM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Annual Report & Notice of AGM

7 Jun 2017 07:00

RNS Number : 3430H
Immupharma PLC
07 June 2017
 

 

 7 June 2017

 

ImmuPharma PLC

("ImmuPharma" or the "Company")

 

 

ANNUAL REPORT AND ACCOUNTS POSTED TO SHAREHOLDERS

NOTICE OF ANNUAL GENERAL MEETING ON 30 JUNE 2017 @ 10.30 AM

 

INVESTOR PRESENTATION TO FOLLOW AT 11.30 AM

 

VENUE: SKY LIGHT CITY, 50 BASINGHALL STREET, LONDON, EC2

 

ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company confirms that today the Annual Report and Accounts for the year ended 31 December 2016 has today been posted to shareholders.

This report includes the 'Annual Report of the Annual General Meeting' ('AGM') as well as the 'Notice of the 2017 AGM', which will be available later today, in electronic form, for download on the Company's website www.immupharma.org.

ImmuPharma's AGM will be held on Friday 30 June at 10:30am at Sky Light City Tower, 50 Basinghall Street, EC2V 5DE.

Investor Meeting @ 11.30am on 30 June 2017

 

ImmuPharma has confirmed that it will be hosting an Investor Presentation and luncheon immediately following the Company's Annual General Meeting at 11.30am. Please contact Lisa Baderoon at lisa.baderoon@immupharma.com if you would like to attend this event.

 

-Ends-

 

 

 

For further information please contact:

 

ImmuPharma plc (www.immupharma.org)

+ 44 (0) 20 7152 4080

Tim McCarthy, Chairman

Lisa Baderoon, Head of Investor Relations

Twitter: @immupharma

 

+ 44 (0) 7721 413496

 

 

 

Northland Capital Partners Limited (Joint Broker)

Patrick Claridge, David Hignell, Corporate Finance

Rob Rees, Corporate Broking

 

 

+44 (0)20 3861 6625

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NOASSAFMMFWSELM
Date   Source Headline
24th Apr 20247:12 amRNSIMMUPHARMA AT BIO-EQUITY 2024 12-14 May
19th Apr 20247:00 amRNSGrant of Share Options
2nd Apr 20247:03 amRNSNew intellectual property strategy initiated
25th Mar 20247:25 amRNSIncanthera provides Comm'l Update/Revenue F'casts
19th Mar 20247:00 amRNSGrant of Share Options
14th Mar 20247:00 amRNSIMMUPHARMA AT BIO-EUROPE SPRING 2024
6th Mar 20247:00 amRNSFinancial, Business and Portfolio Develop't Update
28th Dec 20231:35 pmRNSHolding(s) in Company
19th Dec 20232:50 pmRNSHolding(s) in Company
19th Dec 20237:00 amRNSSimbec-Orion appointed as CRO
18th Dec 20237:15 amRNSIncanthera - Comm'l Skincare Deal/£1M Fundraise
13th Sep 20233:47 pmRNSHolding(s) in Company
7th Sep 20237:00 amRNSResult of Retail Offer and Director Shareholding
31st Aug 20237:02 amRNSWRAP Retail Offer for up to £0.5m
31st Aug 20237:01 amRNSSubscription to raise £1.35m; Sharing Agr, RPT
31st Aug 20237:00 amRNSInterim results
21st Aug 20237:00 amRNSExtension of warrants in Incanthera plc
11th Aug 202312:04 pmRNSDirectorate Change
30th Jun 20231:12 pmRNSResult of AGM
19th Jun 20237:00 amRNSLupuzor Update
6th Jun 20237:00 amRNSIMM RNS Posting of RA and Notice of AGM 30 June 23
18th May 20237:00 amRNSPositive Pre-IND meeting with FDA
11th May 20237:00 amRNSFinal Results
10th May 20231:56 pmRNSHolding(s) in Company
19th Apr 20237:00 amRNSLupozor Update - FDA confirms Type-C meeting date
12th Apr 20237:00 amRNSCIDP P140 Clinical Program Update
27th Mar 20237:00 amRNSLupuzor™ Update
9th Mar 20234:35 pmRNSPrice Monitoring Extension
6th Mar 20237:00 amRNSCollaboration with Orano on ImmuPharma Peptide
6th Feb 20237:00 amRNSLupuzor™ Update
27th Jan 20234:25 pmRNSTR-1: Notification of major holdings
4th Jan 20235:26 pmRNSTR-1: Notification of major holdings
4th Jan 20234:40 pmRNSSecond Price Monitoring Extn
4th Jan 20234:35 pmRNSPrice Monitoring Extension
3rd Jan 20234:58 pmRNSTR-1: Notification of major holdings
22nd Dec 20227:55 amRNSGrant of Options
22nd Dec 20227:00 amRNSEnd of Year Update
22nd Nov 20223:15 pmRNSHolding(s) in Company
14th Nov 20224:40 pmRNSSecond Price Monitoring Extn
14th Nov 20224:35 pmRNSPrice Monitoring Extension
11th Nov 20227:31 amRNSLupuzor Update
11th Oct 20224:40 pmRNSSecond Price Monitoring Extn
11th Oct 20224:35 pmRNSPrice Monitoring Extension
7th Oct 20224:44 pmRNSCompany Secretary Change
6th Oct 20225:17 pmRNSHolding(s) in Company
30th Sep 20227:30 amRNSLupuzor Update
30th Sep 20227:00 amRNSInterim Results or the 6mths Ended 30 June 2022
29th Sep 20224:40 pmRNSSecond Price Monitoring Extn
29th Sep 20224:37 pmRNSPrice Monitoring Extension
14th Sep 202210:04 amRNSWritten Response received from the FDA

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.